Drug Discovery Weekly — October 28, 2026
The FDA has published draft guidance on a new framework to streamline approvals of personalized gene therapies, potentially reducing the need for individual biologics license applications. The Ferring Pharmaceuticals acquisition of Gameto for up to $1.4 billion highlights the ongoing M&A activity in the women's health sector. Additionally, the Moderna and Merck cancer vaccine data has been hailed by clinicians as a significant clinical advancement despite mixed market reactions.
Drug Discovery Weekly — October 28, 2026
FDA Personalized Gene Therapies (FDA) — Draft Guidance
- Indication: Personalized gene editing therapies
- Significance: The FDA published draft guidance that would create an "individualized feature space" framework, allowing updates to personalized gene editing therapies without requiring a new biologics license application for each patient’s customized treatment. This is seen as a win for rare disease advocates who have criticized the agency's previous approach.
- Timeline: The guidance is currently in draft form, with the FDA seeking input from stakeholders.
AstraZeneca Ultomiris (AstraZeneca) — FDA Accelerated Approval
- Indication: Immunoglobulin A nephropathy
- Significance: Ultomiris (ravulizumab) received FDA accelerated approval for its fifth indication, expanding its use in treating Immunoglobulin A nephropathy.
- Timeline: The approval was announced in late October 2026.
Biohaven Vyglxia (Biohaven) — FDA Resubmission Accepted
- Indication: Amyotrophic lateral sclerosis (ALS)
- Significance: The FDA has accepted Biohaven's resubmission for Vyglxia (troriluzole), marking a potential step forward for this experimental ALS treatment.
- Timeline: The resubmission was accepted in late October 2026.
Clinical Trial Milestones
Moderna and Merck Cancer Vaccine (Moderna, Merck) — Phase 2/3 Readout
- Sponsor: Moderna and Merck
- Results: Data from the Moderna and Merck cancer vaccine trial has been described by six melanoma specialists as a clinically meaningful result for melanoma patients who underwent surgery. The vaccine showed significant promise in reducing the risk of recurrence or death.
- What's Next: The companies are expected to seek regulatory approval based on these results.
Eli Lilly Weight Loss Drug (Eli Lilly) — Phase 3 Results
- Sponsor: Eli Lilly
- Results: Eli Lilly reported new results for its weight loss drug, with details on efficacy and safety.
- What's Next: The company is expected to file for regulatory approval based on these results.
Experimental Pancreatic Cancer Drug (Multiple Sponsors) — Clinical Data
- Sponsor: Multiple sponsors
- Results: New results for an experimental pancreatic cancer drug were presented at the ESMO conference.
- What's Next: Further clinical trials and potential regulatory filings.
Pharma Deals & M&A
-
Acquisition: Ferring Pharmaceuticals + Gameto — Up to $1.4 billion Ferring Pharmaceuticals has agreed to acquire next-gen IVF startup Gameto for up to $1.4 billion. The buyout hands Ferring rights to a technology capable of simplifying the lengthy and burdensome process of in vitro fertilization, marking a strategic move into women's health.
-
Licensing Agreement: BioNTech + Bristol Myers Squibb BioNTech has entered into a multi-partner collaboration model with Bristol Myers Squibb for the development of pumitamig. The agreement builds on pumitamig’s existing joint development with Bristol Myers Squibb, demonstrating BioNTech’s strategy of leveraging multiple pharmaceutical partnerships to expand the bispecific’s development across tumor types and combination strategies.
AI & Computational Drug Discovery
- FDA and Rare Disease Advocates: FDA's new draft guidance on personalized gene therapies, which would create an "individualized feature space" framework to update personalized gene editing therapies without a new biologics license application, is seen as a win for rare disease advocates who have criticized the agency approach to these treatments.
Pipeline Watch: Key Upcoming Catalysts
- November 2026: FDA decisions expected on novel agents for stroke prevention, myasthenia gravis, primary biliary cholangitis, GIST, and breast cancer.
Week in Context
This week's developments highlight a significant shift in regulatory approaches, particularly with the FDA's new draft guidance on personalized gene therapies. This framework could dramatically speed up the approval process for customized treatments, addressing long-standing criticisms from rare disease advocates. The Ferring acquisition of Gameto underscores the ongoing M&A activity in the women's health sector, driven by the potential to simplify and improve IVF processes. The clinical data from the Moderna and Merck cancer vaccine trial, despite mixed market reactions, has been recognized by specialists as a major advancement in melanoma treatment, indicating a positive trajectory for cancer immunotherapies.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
